Skip to main content
. 2021 Jan 1;11(4):1970–1981. doi: 10.7150/thno.45777

Figure 3.

Figure 3

Decreased PD-L1 expression after treatment with MS NPs. (A) Western blot image of changes in PD-L1 level from MS NPs-treated MB231 cells. (Lane 1: MB231 cells, lanes 2-4: MB231 cells treated with different concentrations of MS NPs (20 µg/mL, 40 µg/mL, 80 µg/mL respectively.). (B) Densitometric analysis of PD-L1 bands from a. (C) CLSM images of PD-L1 expression in MB231 cells with (upper row) or without (bottom row) MS NPs treatment. (D) PD-L1 expression in MB231 cells with or without MS NPs treatment and measured by flowcytometry. Lines 1-3: MB231 cells, MB231 cells incubated with Alexa Fluor® 647 labelled anti-PD-L1, and MB231 cells treated with MS NPs and incubated with Alexa Fluor® 647 labelled PD-L1 antibody.